Ukip anti-epileptic drugs have been approved for new adaptations in China

According to the drug approval documents issued by China's State Drug Administration (NMPA) on December 7, UCB's application for a new adaptive solution for the injection of zuctrasitan has been approved in China.
according to public information, the drug was approved for the treatment of partial seizures in adults and children over 4 years of age with epilepsy.
screenshot Source: NMPA Website L-Iracetam (trade name: CapeLand) is an anti-epileptic drug developed by Yosepbi.
The drug is a pyridoxine derivative, the mechanism of action is mainly combined with the brain's special subject synactoid vesicle protein SV2A, with central selectivity, through participation in the polymerization of vesicles and cell vomiting to regulate the release of neurotransmitters.
, which was first listed in the U.S. as a tablet in 1999, was approved by the FDA in 2008 and is now considered a gold standard drug for epilepsy treatment.
public information shows that since its approval in China in 2007, Ukip has developed the left ethyl laxitan has been approved several times to treat different epilepsy patients: In 2007, the left ethyl laxitam tablets listed in China, mainly used in adults and children over 4 years of age with partial seizures of the use of treatment; In 2013, the oral solution of zoethiracetam was listed in China for the use of supplemental treatment for partial seizures in adults, children and infants over one month of age;
is worth mentioning that this is also china's only listed original research anti-epileptic needle in 20 years.
, May 2018, the left-ethylene laxitan tablet was approved in China for the use of the addition of epilepsy in adults and adolescents over 16 years of age.
. In August 2018, China's State Drug Administration again approved the listing of the left ethyl rahitan tablet for the treatment of partial seizures (accompanied or not accompanied by secondary comprehensive seizures) in adults and children over 4 years of age.
According to the website of the Drug Review Center (CDE) of the State Drug Administration of China, this approval is for the treatment of partial seizures (accompanied or not accompanied by secondary comprehensive seizures) in patients with epilepsy in adults and children over 4 years of age.
april this year, the application was included in the CDE's priority review.
screenshot Source: CDE Official Website Epilepsy is caused by a group of nerve cells in the brain being activated uncontrolled.
seizures can lead to uncontrollable limb movements, abnormal thinking and behavior, and abnormal perception.
the patient's limb movements can be very intense and lead to loss of consciousness.
childhood epilepsy is a complex disease that can have a significant impact on children's development and function, and is a serious neurological disease common in children and young people, and patients are in urgent need of new treatment options.
。